Headache Clinical Trials | NeuroTrials.ai

Which treatment strategy—withdrawal, prevention (oral, anti-CGRP, botulinum toxin), education, neurostimulation, or combinations—is most effective at reducing monthly headache days in patients with medication-overuse headache?

MOH NMA Liu 2025

Network meta-analysis comparing efficacy of different strategies on medication-overuse headache

The Journal of Headache and Pain · 2025

Bottom Line: Combination therapies—particularly abrupt withdrawal + oral prevention + greater occipital nerve block, and restriction + oral prevention + anti-CGRP(R) therapy—are the most effective initial strategies for medication-overuse headache. Oral prevention, anti-CGRP(R) therapies, and botulinum toxin all significantly reduce monthly headache days with similar efficacy as monotherapies. Abrupt withdrawal alone is…

CLUSTER HEADACHE (CGRP) 1

Is eptinezumab 400 mg IV every 12 weeks safe, tolerable, and effective for long-term prevention of chronic cluster headache?

CHRONICLE

2025

Lancet Neurology

MIGRAINE PROPHYLAXIS 2

Does fremanezumab reduce monthly migraine days and depressive symptoms in patients with migraine and comorbid DSM-5 major depressive disorder?

UNITE

2025

JAMA Neurology

Is amitriptyline an effective migraine prophylactic, and is the benefit independent of its antidepressant action?

Amitriptyline Couch

1976

Neurology

MIGRAINE 1

Does eptinezumab combined with brief patient education reduce migraine burden more than patient education alone in adults with chronic migraine and medication-overuse headache?

RESOLUTION

2026

Neurology

CHRONIC MIGRAINE 3

Which treatment strategy—withdrawal, prevention (oral, anti-CGRP, botulinum toxin), education, neurostimulation, or combinations—is most effective at reducing monthly headache days in patients with medication-overuse headache?

MOH NMA Liu 2025

2025 NEW

The Journal of Headache and Pain

Does adding a 28-day prednisone taper to galcanezumab improve outcomes in medication overuse headache compared with either treatment alone?

Steroids + Galcanezumab for MOH

2025 NEW

Revue Neurologique

Is atogepant effective for preventive treatment of chronic migraine in patients with and without acute medication overuse?

PROGRESS

2024 NEW

Neurology

CLUSTER HEADACHE 2

Do anti-CGRP monoclonal antibodies effectively prevent attacks in episodic and chronic cluster headache?

KOLAKOWSKI ET AL 2026 EFFICACY

2026 NEW

Cephalalgia

Can a CGRP antibody prevent episodic cluster headache attacks?

GALiC

2019

View Details →

MIGRAINE 5

Is vaporized cannabis (THC-dominant, CBD-dominant, or THC+CBD) superior to placebo for the acute treatment of migraine attacks?

CANNABIS MIGRAINE

2024 NEW

medRxiv (preprint)

Does a single intravenous infusion of Lu AG09222, an anti-PACAP monoclonal antibody, reduce migraine days in patients with prior preventive treatment failures?

HOPE

2024 NEW

New England Journal of Medicine

Can a CGRP antibody actually prevent migraines in children and teens?

SPACE - Fremanezumab Pediatric

2026

View Details →

Does early initiation of erenumab in patients with episodic migraine who failed 1 or 2 previous preventive treatments provide improved long-term efficacy, tolerability, adherence, and patient satisfaction compared with nonspecific oral migraine preventive medication?

APPRAISE

2024

JAMA Neurology

Is ubrogepant effective and satisfying as an acute migraine treatment when used with anti-CGRP mAbs, with or without onabotulinumtoxinA, in real-world settings?

COURAGE

2024

Neurology and Therapy